High Blood Pressure Research Council of Australia

HBPRCA Enews May 2011

Greetings from Rob Widdop and the HBPRCA Executive

RobWiddop

Greetings from the e-news desk. We have another action-packed bulletin full of information for the HBPRCA community. Don’t forget to renew your membership if you haven’t done so already. We are asking everyone to use the online form.I’m pleased to say that the additions to our last e-news were well received, even with positive feedback from international members! In this edition, we welcome and feature several more student and full members who have recently joined the Council. We also have a rather provocative opinion piece or ‘Soundbite’ from another elder statesman, Professor John Funder, who has chosen to share his wisdom on aldosterone, rather than comment on a recent influential paper. Again, this highlights the diversity of formats that we welcome for Soundbite! (note: Ed takes responsibility for title).Rob Widdop, HBPRCA Secretary

ISH 2012

ISH 2012 – As you are all aware, the HBPRCA will be hosting ISH 2012 in Sydney, 30 September – 3 October. As members of the HBPRCA, we would like you to advertise the Symposium, by downloading this slide and including it at the end of your presentations. Please click here to download.

  • Are you going to ESH? We will be promoting ISH 2012 – Hypertension Sydney 2012 – at the ESH meeting. It’s really important that HBPRCA members are visible during the refreshment breaks at the promotional stand. Please email the secretariat if you are going – a roster will be drawn up so that everyone gets a chance to be involved!
  • Are you under 40 and willing to be part of the ISH 2012 New Investigator Ambassador Program? The Organising Committee would very much like to attact New Investigators from around the world, and need your help to promote the meeting, with ideas which might appeal to those of similar age and, let’s be real, with the new technology. A great line on your CV …. to be involved, please email the secretariat
  • Have you included the logo in your email signature or made sure you have the slide for use in presentations? All members are encouraged to use these images whenever possible

In This Issue

President’s Message
2011 Annual Scientific Meeting News
Soundbite
Membership Update
Membership Initiatives Research Grants/Project – applications due May 27
Society Liaison News Franco Exchange Applications – applications due May 27
Executive
Upcoming Meetings Travel grants/YI awards @ APCH – abstracts close June 30

President’s Message – Jaye Chin-Dusting

Chin-DustingJaye

It has been a busy couple of months post RGMS. Support for the “Defend the Medical Research Budget” campaign both within and beyond the medical research community was unprecendented and many can now breathe a huge sigh of relief post the May 10 budget. Just this week, World Hypertension Day (WHD) May 17 was another point of focus for many of us at the HBPRCA. Your Exec Council has been working closely with Ogilvy PR to take the “Know your numbers” message out to GPs and the general public. Towards this end we have been working with Boehringer-Ingelheim to extend the Better Blood Pressure project by rolling out first 30 (on WHD), and ultimately 128, Omron HEM 1040 automated BP monitors to multi practitioner clinics across the nation. These are those machines you might have seen at various exhibition stands at conferences; the ones where you stick your whole arm into a narrow tunnel. The idea is to place these machines at waiting rooms (or nurses stations) where the patient will have a play, prompting them to raise the BP/know your numbers discussion with their GP. There will be supporting written material available to the patients. This is supported by an unrestricted grant to the HBPRCA from Boehringer-Ingelheim.

As well we will have delivered the “Don’t wait till it’s too late” posters to over 5,000 GPs – with the help of Novartis, sanofi-aventis and Boehringer Ingelheim, prompting them to regularly take their patients’ BP. This message has also been sent out to Research Organisations across the country via our senior membership. The hope is that the “Don’t wait ‘til it’s too late message” will be featured on each institute website with a link to a HBPRCA/Hypertension researcher within that organisation.

If that is not enough, the HBPRCA has also received a separate grant from Boehringer-Ingelheim to work with Ogilvy to do a media blitz for WHD. HBPRCA spokespersons from each state were ‘volunteered’ and I am very grateful to all of them for their time. At the last count – 34 radio pieces, 9 newspaper, 1 television (Channel 7) and 3 GP publications  have all featured WHS and/or the HBPRCA. But wait, there’s  more … thanks also to the HBPRCA members who cajoled their insitutes to running stories on their websites and/or newspapers.

For the researcher, don’t forget that we are offering grant seed funding (~$10,000) to members to help move that brilliant idea along. Open to all members, we look forward to receiving many applications. Dateline is May 27.

I am also pleased to announce that abstracts from the 2010 Annual Scientific Meeting were e-published on May 9, and will be included in the July print version of Hypertension. Again, our thanks to Servier Australia for their support of this important HBPRCA activity.

Abstracts From the 32nd Annual Scientific Meeting of the High Blood Pressure Research Council of Australia. Hypertension. May 9, 2011.
DOI: 10.1161/HYP.0b013e3182190959.  http://hyper.ahajournals.org/cgi/reprint/ HYP.0b013e3182190959. Accessed xxxx

2011 Annual Scientific Meeting News from Anne Barden and Jim Sharman

As Jaye mentioned, please check out airfares and accommodation now – we really would like to see you in Perth, for the 2011 Annual Scientific Meeting (December 7 – 9). Just last week fares were $189 each way from Melbourne!

Highlights

  • Professor Peter Rothwell, Professor of Clinical Neurology, John Radcliffe Hospital Oxford – RD Wright Lecture
  • Professor Rob Parton, University of Queensland – Austin Doyle Lecture
  • Associate Professor Martin Ng, University of Sydney – Colin I Johnston Lecture
  • Wednesday is conjoint with ASCEPT and AuPS – a great chance for networking!
  • Joint conference dinner on Wednesday evening
  • Student symposium and function on Tuesday evening
  • Student poster judging (yes, the students adjudicate on the poster quality) will be incorporated
  • ANCHA will again be joining us – please make sure any nurses working in the field know about the meeting
  • Student registration fees will be highly subsidised by HBPRCA

We look forward to seeing you in Perth – Anne Barden and Jim Sharman

ISH 2012 – Hypertension Sydney

ISH 2012 logoThe excitement is beginning to build as we look forward to the next ISH Scientific Meeting in Sydney from the 29th September to the 4th October 2012. Many people have already blocked out their diaries, knowing that there is no better opportunity to experience the combination of a great meeting and a unique destination. The Sydney Harbour is one of the most beautiful in the world and the Conference centre sits right on the water’s edge adjacent to marvellous restaurants and other attractions (see www.ish2012.org/venue.asp).

However, it’s the quality of the meeting that is the major attraction. The program is already well developed around the theme “The future of cardiovascular protection.” There are some excellent pre- and post-meeting satellites providing focussed gatherings around contemporary clinical and research issues. Indeed, there is still time for those wishing to add to the existing list to do so via the website (www.ish2012.org/satellitemeetings.asp). During the Main Meeting there are Plenary Sessions and Symposia that will showcase the latest medical breakthroughs and scientific discoveries, delivered by the leaders in the field.

We are delighted and honoured to announce that among these leaders are 2 Nobel Laureates – Peter Doherty and Bert Sakmann.

  • Peter Doherty was awarded the Nobel Prize for Physiology or Medicine in 1996 for his discoveries concerning the specificity of the cell mediated immune defence. At that time, one could not have predicted the relevance and excitement around immunity in blood pressure and cardiovascular disease, but his presence at Hypertension Sydney 2012 will a highlight in sessions dedicated to the remarkable advances in this area.
  • Bert Sakmann won his Nobel Prize in 1991 for his pioneering work on cellular electrophysiology and ion channels and continues to lead in neurophysiology. His participation will ensure that sessions devoted to neural mechanisms in blood pressure and cardiovascular disease will be of the highest international standard.

Some of the other major themes include blood pressure variability, renal denervation, stroke and dementia, biomarkers and genetics, modern therapeutic advances, epidemiology, diabetes, vascular hemodynamics, pregnancy and a host of issues of interest to clinicians and scientists alike.

Hypertension Sydney 2012 is a conjoint meeting with the Asia Pacific Society of Hypertension. This will provide an opportunity to emphasise the important work in this rapidly growing region. We are certain also that many participants will look forward to augmenting the new knowledge obtained from the meeting with some great memories of Australia and the Asia-Pacific region on their way into or out of Sydney next year. For further information please visit our website www.ish2012.org or contact ish2012@arinex.com.au.

Garry Jennings – Chair, Organising Committee

Soundbite: Aldosterone Funder-mentals

John Funder, Senior Fellow, Prince Henry’s Institute of Medical ResearchFunder

There are things we know, things we don’t know, and some things we may never know. We were taught that primary aldosteronism is a rare (<1%) and benign form of hypertension: now we know this to be not true. Now we know that around the world, primary aldosteronism accounts for ~10% of hypertension, with a much higher rate of cardiovascular sequelae –atrial fibrillation, myocardial infarction, stroke – than in age-, sex- and blood pressure-matched essential hypertensives. From clinical studies we know that mineralocorticoid receptor antagonists lower blood pressure as effectively as current first line antihypertensives in essential hypertension and at low doses are both uniquely vasoprotective in essential hypertension and spectacularly effective in so-called resistant hypertension.

There are ten times more cardiologists than endocrinologists in most countries; and while endocrinologists write the guidelines for primary aldosteronism, cardiologists write the guidelines for hypertension.

We know how to do basic maths. If the prevalence of hypertension in Australia is a conservative 15%, then we have over 300,000 people with primary aldosteronism. Of this group, a maximum of perhaps 300 patients per year are diagnosed and treated, or 0.1%. What we are seeing – or perhaps not seeing – is the tip of the iceberg, and we don’t appear to know what to do for the other 99.9% of the group. Low dose spironolactone is vascular protective in essential hypertension, makes the difference in resistant hypertension, and is game-changing for primary aldosteronism – specific for bilateral adrenal hyperplasia (the majority), and much better than no targeted medical treatment in aldosterone producing adenoma. The cost is minimal, and dwarfed by the personal and societal costs in terms of morbidity, mortality, loss of productivity and medical care if the condition goes untreated.

Something I may never know, given the disconnect between who writes the guidelines, is why we pay lip-service to evidence-based medicine, but do not include low dose spironolactone as the first-line treatment for hypertension.

Membership News from Janna Morrison

JannaMorrisonThank you to those of you (about 200!) who have taken the time to renew your membership in the HBPRCA . It is a great time to be part of this vibrant and growing scientific society. If you haven’t yet renewed your membership, please visit the Meetings First website via this link, log in, follow the prompts, and voila! All done. Membership renewal was due by March 31! Don’t forget, students don’t pay membership fees – so why not invite appropriate colleagues to be a member?

Thanks also to everyone for completing the “extra questions”  – in the next issue, there will be an analysis of members – how many teach, other societies, research interests .. the data certainly looks fascinating!

Member Profiles

New student member – Linda Gallo

New full member – Natalie Lumsden

Linda GalloI completed a Bachelor of Science with Anatomy and Physiology majors at The University of Melbourne in 2007. This was followed by an Honours year in the Department of Physiology, supervised by Dr Andrew Siebel, A/Prof Mary Wlodek and Prof Glenn McConell. I examined the effects of exercise training on diabetic outcomes associated with fetal growth restriction in male rats. In 2009, I was awarded a National Heart Foundation Postgraduate Scholarship to begin my PhD with A/Prof Mary Wlodek at The University of Melbourne, co-supervised by A/Prof Karen Moritz (University of Queensland). I am currently in my third year, investigating the developmental origins of hypertension and renal disease. Specifically, my research focuses on maternal cardiorenal adaptations to pregnancy in growth restricted rats, long-term maternal health outcomes and intergenerational transmission of hypertension and renal disease. My project is carried out in collaboration with Dr Luise Cullen-McEwen in the Department of Anatomy and Developmental Biology and A/Prof Kate Denton in the Department of Physiology, both at Monash University. I plan to submit my thesis early next year and look forward to overseas post-doctoral opportunities in the cardiovascular/renal field. NatalieLumsdenI trained within the Department of Pharmacology, Monash University (2002-2005) under the supervision of Assoc/Prof Wayne Hodgson where my research employed various classical in vitro and in vivo pharmacological techniques to evaluate the bioactivity of snake venoms. To compliment this I moved to the University of Queensland to undertake postdoctoral training with Prof Richard Lewis in analytical chemistry techniques such as electrospray ionisation and MALDI-TOF mass spectrometry, in addition to high through-put functional assays to help guide the identification of novel pharmacologically active constituents from natural products that may be useful in the development of chronic pain therapies or anti-cancer treatments. In 2007 I moved into cardiovascular research which has been a mix of academic and commercial research, first at University College London, under the supervision of Assoc Prof Adrian Hobbs, where we focused on the vascular pharmacology of guanylate cyclase receptors, and now within the Vascular Pharmacology laboratory of Professor Jaye Chin-Dusting at the Baker IDI Heart and Diabetes Research Institute. Here our research focuses on vascular dysfunction in various cardiovascular disease settings, and the unstable plaque, using laboratory and clinical based research, the latter in collaboration with Prof Anthony Dart, the Heart Centre, Alfred Hospital. I still dabble in natural products but with a focus on cardiovascular benefits of traditional medicines and functional foods.
New student member – Melissa Tjongue New full member – Hitesh Peshavariya
MelissaTjongueAfter completing a Bachelor of Science degree at Monash University in Clayton, Melbourne, I went on to complete an Honours degree with A/Prof Kate Denton and Dr Marianne Tare in 2009, where I looked at the effects of chronic maternal alcohol consumption on arterial pressure and the renal artery function in the offspring during adulthood. I have just recently entered the second year of my PhD where I am currently examining the regrowth of the renal nerves post-denervation. Studies have shown that a recently developed catheter-based renal denervation method has thus far been effective in attenuating arterial pressure in resistant hypertensive patients. However, the functionality of the renal nerves post-chronic denervation has yet to be investigated. For my research, I will be establishing a time course of renal vascular reinnervation, determining whether there is an association between attenuation of arterial pressure and renal vascular reinnervation in spontaneously hypertensive rats (SHR), and examining the effects of renal denervation on the neuroeffectors in the SHR once reinnervation is established. My project aims to elucidate the functionality of renal nerves post-denervation and whether or not the nerves have been permanently altered. I completed my B.Sc. and M.Sc. degrees in Biochemistry, followed by more than six years as a full time researcher at two different research centres in India. I worked as a Research Fellow at the Gujarat Cancer Research Institute (1997-2000) where I studied the role of antioxidant enzymes in tobacco-induced head and neck cancers. We discovered that higher levels of antioxidant enzymes in tumour-adjacent normal tissues were associated with the failure of post-surgical radiotherapy. In 2000, I joined the Cellular and Molecular Biology Lab at Torrent Pharmaceutical Research (2000-2004), where I worked with a drug discovery team and the task was to discover drugs for their anti-apoptotic activity and use the leading compound for cardioprotection and neuroprotection. Leading compounds (TRC-051384) are sucessful in phase-I clinical trials. In 2004, I migrated to Australia and was fortunate to receive the Dora Lush (NHMRC) scholarship to commence my PhD with Prof. Greg Dusting at Howard Florey Institute, where I studied the role of NADPH oxidase and its isoforms in vascular biology. I won the prestigious TJ Martin award (2009) for the best PhD thesis at St.Vincent’s Hospital research campus of the University of Melbourne. I found an effective way of modulating NADPH oxidase isoform expression, and regualtion of endothelial cell proliferation and angiogenesis. I continued my post-doctoral studies on TGFβ, prostacyclin receptor and NADPH oxidase siganlling in angiogenesis, stem cells and cardiovascular diseases under the mentorship of Prof. Dusting at O’Brien Institute. Over the past 13 years, I have developed many skills in the fields of molecular and cellular biology and animal models, and a strong passion for oxidant siganlling research into the regulation of cell proliferation and angiogenesis in cardiovascular diseases. Becoming a member of the HBPRCA provides a great opportunity to be a part of cardiovascular research community and interact with council member.

Member Initiatives

CALL FOR INTEREST IN PARTICIPATION OF THE ‘EXERCISE-BP-CONTROL STUDY’ – AN INITIATIVE SUPPORTED BY THE EXECUTIVE COMMITTEE OF THE HBPRCA

The general aim of this initiative is to determine the prognostic utility of BP acquired during an exercise stress test to predict BP control. The findings may help improve the identification of individuals at higher risk related to BP who may otherwise go undetected. If you have access to BP acquired during an exercise stress test, as well as ambulatory (or home) BP data and basic clinical information on these individuals, please read on……

Background
Healthy people with ‘normal’ BP at rest (<140/90 mmHg) but an exaggerated BP response to exercise (e.g. ≥210/105 mmHg in men or ≥190/105 mmHg in women) are at significantly greater risk of cardiovascular events and mortality. Interestingly, exercise BP predicts future development of hypertension and cardiovascular outcomes independent from resting blood pressure. The reasons underlying the additional prognostic value of exercise BP beyond resting BP are unknown. However, recent data suggests that people with exaggerated exercise BP may have masked hypertension (‘normal’ clinic BP and raised BP outside the clinic) and this could be a major factor contributing to increased risk.

This also raises the possibility that individuals at increased risk related to BP may be identified from the BP response to exercise. Exercise stress testing is commonly used to screen for myocardial ischaemia. The test is usually supervised by a clinician who records resting BP as well as the exercise BPs through increasing intensity of effort. An exaggerated BP response may be noted as an abnormality of the exercise test, but there are no guidelines as to appropriate management thereafter. To our knowledge there has never been a study to determine if exercise BP can help identify BP control and this is the principle aim of the initiative. It is hypothesised that an exaggerated BP response to exercise will have good sensitivity and specificity for predicting the presence of masked hypertension.

Data required for analysis**

  • Exercise BP (acquired during a conventional exercise stress test – preferably including BPs at all levels of exercise)
  • Clinic BP
  • Out of office BP (24 ABPM or home BP)
  • Basic patient characteristics (e.g. age, gender, BMI, antihypertensive medications)

**Since the presence of left ventricular dysfunction due to coronary artery disease is known to impair the ‘normal’ exercise BP response, it will be important to know the result of the exercise stress test (i.e. positive or negative for ischaemia) or other relevant clinical tests to rule out coronary artery disease.

Similar to the recent ABPM initiative headed by Geoff Head it is expected that pooling data from several thousand study participants will be required to assess the study question. Findings are expected to be published in a peer-reviewed journal with authorship offered to contributing parties.

Would those interested in participating this this initiative please email James.Sharman@menzies.utas.edu.au

ANNOUNCEMENT – BETTER BLOOD PRESSURE MEASUREMENT INITIATIVE RESEARCH GRANTS

In 2004, the High Blood Pressure Research Council of Australia established the Better Blood Pressure Measurement initiative with the support of Servier Australia Ltd. Through this initiative the Council has supported several important research projects regarding the measurement of blood pressure. These have included grants to:

The Executive would like to announce that two grants of AUD10,000 + GST will be made available during 2011. It is envisaged that these grants might be used to fund small projects in the broader area of blood pressure, perhaps in generating pilot data needed for a larger application to another funding body.

Expressions of interest should be no longer than 2 pages and should include potential investigators, rationale, experimental design and an indicative budget. They should be sent to the Secretariat by email to be received no later than Friday 27 May.

Ambulatory Blood Pressure Monitoring (ABP) Working Group Initiative

Members: Geoff Head, Susie Mihailidou, Karen Duggan, Alexandra Bune, James Sharman, Arduino Mangoni, Peter Howe, Narelle Berry, Diane Cowley, Michael Stowasser, Lawrie Beilin, Jonathan Hodgson, John Chalmers, Carla Morey, Mark Nelson, Mark Brown, Barry McGrath, Markus Schlaich and John Ludbrook

Members of the Council’s ABP working group are now participating in updating the ABP Position Statement for the National Heart Foundation. These are Geoff Head, Susie Mihailidou, Michael Stowasser, Mark Nelson, Barry McGrath and Markus Schlaich. This is a joint undertaking of the National Heart Foundation and the Council and includes Jinty Wilson as National Manager – Clinical Programs for the NHF. The draft document was presented at the Annual Scientific Meeting last December during the morning ABP workshop. Since that time we have been in the consultative phase with various interested parties who have made substantive and valuable contributions. The main aim of the update to the 2002 statement was to include the findings of the working group which was published last year in the BMJ (Head G, Mihailidou A, Duggan K, Beilin L, Berry N, Brown M, Bune A, Cowley D, Chalmers J, Howe P, Hodgson J, Ludbrook J, Mangoni A, McGrath B, Nelson M, Sharman J, Stowasser M. Definition of ambulatory blood pressure targets for diagnosis and treatment of hypertension in relation to clinic blood pressure: prospective cohort study. Brit Med J. 2010;340:c1104). We also wanted to include all recent pertinent information on the use of ABP. We hope to finalise this process shortly and will be ready for release mid year. In the process we have continued to promote comment by presenting the draft at the Heart Foundation Conference in March and at up and coming meetings in Milan (oral presentation at European Society of Hypertension meeting) and at the Cardiac Society Meeting in Perth in August. Mark Nelson is also preparing to submit an abstract to the Royal Australian College of General Practitioners meeting in Hobart in October.

In other news:

  • Geoff Head will present to the satellite of the ESH meeting entitled. “Consensus Meeting on Ambulatory Blood Pressure Monitoring” in June representing the Australian ambulatory data base which was collected by the working group.
  • ARTEMIS International Database of which we have a small representation so far, will present at the ESH meeting the first abstract. The abstract was submitted as a late breaking and will be an oral presentation entitled “ HYPERTENSION PHENOTYPES DEFINED BY OFFICE AND AMBULATORY BLOOD PRESSURE IN 9,153 SUBJECTS REFERRED TO HYPERTENSION CLINICS IN FOUR CONTINENTS: THE ARTEMIS INTERNATIONAL REGISTRY”

Society Liaison News from Chris Reid

ChrisReidThe HBPRCA has formal links with ASMR, the BHS, the AHA Council for High Blood Pressure Research, ISH, APSH, the NHF and the French Hypertension Society.

Parlez vous Francais? Franco Australian Exchange Program

The HBRPCA maintains a link with our French counterparts Société Française d’Hypertension Artérielle (SFHTA) in which we will provide financial support (airfare and accommodation) for members wishing to spend a short time (1-3 month(s)) working in a laboratory in each other’s country. The exchange program will sponsor one person each way, fostering collaborative projects between French and Australian Hypertension researchers. There are no age limits or prerequisites apart from being a member of either group. To apply complete the application form and send to the HBPRCA secretariat, along with your CV. Please be sure you have agreement of the host laboratory before you apply.

  • The deadline for applications is Friday 27 May 2011 – for travel during 2012
  • To download an application form, please click FrancoExchangeAppForm
  • Applications will be judged by a panel of the HBPRCA Executive Committee and notification expected to be made within 4 weeks of the application deadline.
  • The degree of support is anticipated to be AUD$2,500 toward the airfare and 900 euros per month towards the cost of accommodation (approx AUD7000 max).
  • The winner will be required to write a feature article (in English) with photos for the e-news!!

We would like to thank Servier Laboratories for their continued support of this program.

International Society of  Hypertension joins Facebook and Twitter

The New Investigator Committee (NIC) of the International Society of Hypertension (ISH) was recently established, with the primary aim to support and encourage new investigators in blood pressure and related research. A key element is the formation of a Hypertension Future Leaders Group (HFLG); a network for new investigators run by new investigators. The mission of the HFLG is to facilitate the participation of, and interaction between, students and new investigators in hypertension research. The HFLG welcomes any student or new investigator with a passion for hypertension research and who is aiming to grow as a future leader in the field. Membership will be designed for those within 10 years of a doctoral degree.

Stephen Harrap, ISH President,  is delighted to announce that one aspect is an an ISH New Investigators Network on Facebook: http://www.facebook.com/ISHNIN and Twitter (ISHNIN). This initiative is designed to put New Investigators (RHD students and post-doc researchers within 10 years of graduation – allowing for career interruption) around the world in contact with one another. It will also spread news of new ISH initiatives for New Investigators including a special satellite meetings (Hypertension Future Leaders Meetings), the first of which will occur in Orlando before the CHBPR meeting. These satellites will be devised and run by New Investigators themselves. And, there is a competition to design a logo for the network. In time, a new Mentorship scheme will be developed. Australian New Investigators are invited to be involved. To learn more, please contact the ISH Secretariat.

ASMR

Two pieces of correspondence members may be interested in

  • Minutes of the recent meeting of ASMR Directors with Affiliate Member Representatives
  • Thanks!

“Last evening I represented ASMR at the 2011-2012 Budget lock down. ASMR would like to congratulate the Gillard Government in maintaining investment in the National Health and Medical Research Council. In the face of the ongoing global financial crisis and domestic environmental disasters affecting the lives of many Australians, we believe this outcome reflects the government’s confidence in the health and medical research sector to underpin many aspects of the global and domestic recovery process.

Australian health and medical research has a distinguished track record and the sector will continue to contribute provided investment in the critically important NHMRC keeps pace with the health needs of Australia. In the coming decades, innovative initiatives which link government investment in health and medical research to the health needs of the population will be an imperative to ensure a healthy and economically viable Australia.

I would like to extend my personal thanks to all our members for responding to our grass roots campaign; writing letters to their local members, the PM and other politicians in support of preserving government investment in NHMRC in the Federal Budget 2011/12. ASMR would also like to congratulate the WEHI DiscoveriesNeedDollars Campaign and Research Australia’s electronic petition. It is important that we continue this momentum.

Health and Medical Research underpins health and health reform, saves lives and money.”

Dr Emma Parkinson-Lawrence | President ASMR

British Hypertension Society invites HBPRCA members to attend their meeting

For the first time in its 30 year history, the meeting is open to both members and non-members and you are invited to submit abstracts (deadline: 3rd May 2011). The Society wrote saying they very much look forward to welcoming the HBPRCA winner from last December, Eduardo Pimenta, to the conference, and espeically invited HBPRCA to attend and may register at BHS members rates. BHS 2011 – Main Announcement and Call for Abstracts

Who are the Executive – really? Or should that be ‘realmente’?

Each e-news, we will highlight one or two of the Executive so that members get to know them better. This issue, Eduardo Pimenta – Clinical Liaison.

Eduardo PimentaI am happy to be a member of the Executive Committee of the High Blood Pressure Research Council of Australia. I am a physician from Sao Paulo, Brazil, trained in internal medicine, cardiology and hypertension/nephrology. I have been working with clinical hypertension research since 2006 when I started my postdoctoral research fellow at the University of Alabama at Birmingham, USA, with Professors Suzanne Oparil and David Calhoun. Since then, my main interest has been the effects of salt and aldosterone in the cardiovascular system, kidneys and obstructive sleep apnoea. I have been in Australia since February 2009 and all members of the HBPRCA have been very welcoming, especially Prof. Michael Stowasser who has given me unlimited support. I am working as a Senior Lecturer in the University of Queensland School of Medicine and Clinical Research Fellow in the Endocrine Hypertension Research Centre at Princess Alexandra Hospital, Brisbane. I started my role in the HBPRCA as student liaison, but, because of my previous clinical experience and increased interest from GPs and other health professionals in blood pressure, I am now the Clinical Liaison  Executive [ed: which means Eduardo gets to draft all the answers to tricky questions]. All members (and potential members) should not hesitate in contacting me if they have any question, suggestion or comment.

Meetings in 2011

1st Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) 2-5 June 2011
Kerry Hotel Pudong, Shanghai, China
Click here for meeting website
8th Asian-Pacific Congress of Hypertension 2011 (8th APCH 2011) 24 – 27 November 2011
Taipei International Convention Center (TICC), Taiwan
Click here for meeting website APSH invite HBPRCA members to attend. To assist the attendance of young investigators (<45y) there are a number of young investigator awards ($1000US) together with complimentary registration. There is also a Young Investigators Award ($1000US) for the best oral presentation. Details about the meeting can be obtained an www.apch2011.tw and the secretariat can be contacted on secretariat@apch2011.tw

Acknowledgements

Corporate Members MemberLogos
Corporate Sponsors SponsorLogos

Edit